HDAC11 is a novel drug target in carcinomas

ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform

Rhodes, D. R., Yu, J., Sundaram, S. K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T. R., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,615 · see citing works

Histone deacetylases (HDACs): characterization of the classical HDAC family

RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114 · see citing works

Anticancer activities of histone deacetylase inhibitors

Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · see citing works

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

Haberland, M., Montgomery, R. L., & Olson, E. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,541 · see citing works

Epigenetic therapy of cancer: past, present and future

Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,291 · see citing works

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

Yang, X., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,239 · see citing works

HDAC family: What are the cancer relevant targets?

Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069 · see citing works

Histone deacetylases and cancer

Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031 · see citing works

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

Kelly, W. K., O’Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M. L., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Secrist, J. P., Schwartz, L. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 906 · see citing works

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744 · see citing works

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention

Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3214 · Cited by 494 · see citing works

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

Villagra, A., Cheng, F., Wang, H.-W., Suarez, I., Glozak, M., Maurin, M., Nguyen, D., Wright, K. L., Atadja, P. W., Bhalla, K., et al. (2009) · Nature Immunology · doi:10.1038/ni.1673 · Cited by 455 · see citing works

AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression

Zeng, Y.-X., Somasundaram, K., & El‐Deiry, W. S. (1997) · Nature Genetics · doi:10.1038/ng0197-78 · Cited by 280 · see citing works

Isoform-specific histone deacetylase inhibitors: The next step?

Balasubramanian, S., Verner, E. J., & Buggy, J. J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.013 · Cited by 224 · see citing works

Bone Morphogenetic Protein 4 Induces Differentiation of Colorectal Cancer Stem Cells and Increases Their Response to Chemotherapy in Mice

Lombardo, Y., Scopelliti, A., Cammareri, P., Todaro, M., Iovino, F., Ricci–Vitiani, L., Gulotta, G., Dieli, F., de Maria, R., & Stassi, G. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.005 · Cited by 222 · see citing works

Cloning and characterization of a novel human histone deacetylase, HDAC8

BUGGY, J. J., SIDERIS, M. L., MAK, P., LORIMER, D. D., MCINTOSH, B., & CLARK, J. M. (2000) · Biochemical Journal · doi:10.1042/bj3500199 · Cited by 197 · see citing works

High-throughput detection and multiplex identification of cell contaminations

Schmitt, M., & Pawlita, M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp581 · Cited by 142 · see citing works

AK2 activates a novel apoptotic pathway through formation of a complex with FADD and caspase-10

Lee, H.-J., Pyo, J.-O., Oh, Y., Kim, H.-J., Hong, S.-H., Jeon, Y.-J., Kim, H., Cho, D.-H., Woo, H., Song, S., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1650 · Cited by 97 · see citing works

Acetylation/Deacetylation Modulates the Stability of DNA Replication Licensing Factor Cdt1

Glozak, M. A., & Seto, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809394200 · Cited by 84 · see citing works

Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer

Becker, J. C., Fukui, H., Imai, Y., Sekikawa, A. M., Kimura, T., Yamagishi, H., Yoshitake, N., Pohle, T., Domschke, W., & Fujimori, T. (2007) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520701192383 · Cited by 83 · see citing works

C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells

Huang, M.-C., Chen, H., Huang, H.-C., Huang, J. C., Liang, J.-T., Shen, T.-L., Lin, N.-Y., Ho, C., Cho, I.-M., & Hsu, S.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209350 · Cited by 79 · see citing works

Wnt signaling and colon tumorigenesis — A view from the periphery

Burgess, A. W., Faux, M. C., Layton, M. J., & Ramsay, R. G. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.010 · Cited by 72 · see citing works

Targeting Histone Deacetylases in Neuroblastoma

Witt, O., Deubzer, H. E., Lodrini, M., Milde, T., & Oehme, I. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315774 · Cited by 70 · see citing works

Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models

Haendler (2009) · International Journal of Oncology · doi:10.3892/ijo_00000406 · Cited by 66 · see citing works

Agonists of an ecdysone-inducible mammalian expression system inhibit Fas Ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO

Oehme, I., Bösser, S., & Zörnig, M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401730 · Cited by 48 · see citing works

Histone deacetylase inhibitor Helminthosporium carbonum (HC)‐toxin suppresses the malignant phenotype of neuroblastoma cells

Deubzer, H. E., Ehemann, V., Westermann, F., Heinrich, R., Mechtersheimer, G., Kulozik, A. E., Schwab, M., & Witt, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.23295 · Cited by 40 · see citing works

The Target Discovery Process

Egner, U., Krätzschmar, J., Kreft, B., Pohlenz, H., & Schneider, M. (2005) · ChemBioChem · doi:10.1002/cbic.200400158 · Cited by 35 · see citing works

Romidepsin: A Guide to its Clinical Use in Cutaneous T-Cell Lymphoma

Lyseng-Williamson, K. A., & Yang, L. P. H. (2011) · American Journal of Clinical Dermatology · doi:10.2165/11208520-000000000-00000 · Cited by 10 · see citing works

New and emerging HDAC inhibitors for cancer treatment

West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · see citing works

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097 · see citing works

Histone Modifications and CancerPreprint

Audia, J. E., & Campbell, R. M. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019521 · Cited by 1,024 · see citing works

Histone Deacetylases and Mechanisms of Regulation of Gene Expression

Chen, H. P., Zhao, Y., & Zhao, T. C. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2015012997 · Cited by 308 · see citing works

Targeting histone deacetylases for cancer therapy: Trends and challenges

Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222 · see citing works

HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2

Cao, J., Sun, L., Aramsangtienchai, P., Spiegelman, N. A., Zhang, X., Huang, W., Seto, E., & Lin, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815365116 · Cited by 189 · see citing works

Lysine acetylation and cancer: A proteomics perspective

Gil, J., Ramírez-Torres, A., & Encarnación‐Guevara, S. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.10.003 · Cited by 188 · see citing works

HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness

Bi, L., Ren, Y., Feng, M., Meng, P., Wang, Q. L., Chen, W., Jiao, Q., Wang, Y., Du, L., Zhou, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3044 · Cited by 186 · see citing works

Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials

Hontecillas‐Prieto, L., Flores-Campos, R., Silver, A. R., de Álava, E., Hajji, N., & García-Domínguez, D. J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.578011 · Cited by 182 · see citing works

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Mithraprabhu, S., Kalff, A., Chow, A. L., Khong, T. T., & Spencer, A. G. (2014) · Epigenetics · doi:10.4161/15592294.2014.983367 · Cited by 176 · see citing works

Histone deacetylase inhibitors in hematological malignancies and solid tumors

Chun, P. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0571-1 · Cited by 147 · see citing works

Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy

Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 134 · see citing works

Targeting Histone Deacetylases in Diseases: Where Are We?

Benedetti, R., Conte, M., & Altucci, L. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5776 · Cited by 127 · see citing works

HDAC11: a rising star in epigenetics

Liu, S., Wu, F., Jin, Y., Weiqin, C., & Xu, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110607 · Cited by 116 · see citing works

Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells

Wawruszak, A., Kałafut, J., Okoń, E., Czapiński, J., Hałasa, M., Przybyszewska-Podstawka, A., Miziak, P. A., Okła, K., Rivero‐Müller, A., & Stepulak, A. (2019) · Cancers · doi:10.3390/cancers11020148 · Cited by 103 · see citing works

Histone deacetylases function as novel potential therapeutic targets for cancer

Zhang, H., Shang, Y., Chen, H., & Li, J. (2016) · Hepatology Research · doi:10.1111/hepr.12757 · Cited by 99 · see citing works

Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function

Huang, J., Wang, L., Dahiya, S., Beier, U. H., Han, R., Samanta, A., Bergman, J., Sotomayor, E. M., Seto, E., Kozikowski, A. P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09211-3 · Cited by 96 · see citing works

Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next

Thaler, F., & Mercurio, C. (2013) · ChemMedChem · doi:10.1002/cmdc.201300413 · Cited by 95 · see citing works

Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2

Bora-Singhal, N., Mohankumar, D., Saha, B., Colin, C., Lee, J. Y., Martin, M. W., Zheng, X., Coppola, D., & Chellappan, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-61295-6 · Cited by 96 · see citing works

Activity-Guided Design of HDAC11-Specific Inhibitors

Son, S. I., Cao, J., Zhu, C., Miller, S. P., & Lin, H. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00292 · Cited by 85 · see citing works

Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer

Rana, Z., Diermeier, S. D., Hanif, M., & Rosengren, R. J. (2020) · Biomedicines · doi:10.3390/biomedicines8020022 · Cited by 84 · see citing works

HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes

Núñez‐Álvarez, Y., & Suelves, M. (2021) · FEBS Journal · doi:10.1111/febs.15895 · Cited by 82 · see citing works

Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer

Dekhne, A. S., Hou, Z., Gangjee, A., & Matherly, L. H. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0423 · Cited by 79 · see citing works

HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities

Koeneke, E., Witt, O., & Oehme, I. (2015) · Cells · doi:10.3390/cells4020135 · Cited by 74 · see citing works

Microtubule associated proteins as targets for anticancer drug development

Khwaja, S., Kumar, K., Das, R., & Negi, A. S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105320 · Cited by 76 · see citing works

Characterization of Histone Deacetylase Mechanisms in Cancer Development

Hai, R., He, L., Shu, G., & Yin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700947 · Cited by 67 · see citing works

HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.

Shan, W., Jiang, Y., Yu, H., Huang, Q., Liu, L., Guo, X., Li, L., Mi, Q., Zhang, K., & Yang, Z.-Q. (2017) · Europe PMC (PubMed Central) · Cited by 68 · see citing works

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Yue, L., Sharma, V., Horvat, N. P., Akuffo, A. A., Beatty, M. S., Murdun, C., Colin, C., Billington, J. M. R., Goodheart, W. E., Sahakian, E., et al. (2020) · Blood · doi:10.1182/blood.2019895326 · Cited by 67 · see citing works

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival

Thole, T. M., Lodrini, M., Fabian, J., Wuenschel, J., Pfeil, S., Hielscher, T., Kopp-Schneider, A., Heinicke, U., Fulda, S., Witt, O., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.49 · Cited by 67 · see citing works

Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression

Ratovitski, E. A. (2017) · Current Genomics · doi:10.2174/1389202917666160803165229 · Cited by 64 · see citing works

Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer

Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 60 · see citing works

HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription

Yuan, Y., Zhao, K., Yao, Y., Liu, C., Chen, Y., Li, J., Wang, Y., Pei, R., Chen, J., Hu, X., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104619 · Cited by 60 · see citing works

Histone deacetylases and atherosclerosis

Zheng, X., Zhou, T., Wang, X., Tong, X.-H., & Ding, J. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.048 · Cited by 56 · see citing works

Targeting Lysine Deacetylases (KDACs) in Parasites

Wang, Q., Rosa, B. A., Nare, B., Powell, K., Valente, S., Rotili, D., Mai, A., Marshall, G. R., & Mitreva, M. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004026 · Cited by 56 · see citing works

HDACs and the epigenetic plasticity of cancer cells: target the complexity

Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55 · see citing works

ST7612AA1, a Thioacetate-ω(γ-lactam carboxamide) Derivative Selected from a Novel Generation of Oral HDAC Inhibitors

Giannini, G., Vesci, L., Battistuzzi, G., Vignola, D., Milazzo, F. M., Guglielmi, M. B., Barbarino, M., Santaniello, M., Fantò, N., Mor, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5008209 · Cited by 48 · see citing works

HDAC11 deletion reduces fructose-induced cardiac dyslipidemia, apoptosis and inflammation by attenuating oxidative stress injury

Fan, X., Wan, L., Duan, M., & Lu, S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.090 · Cited by 48 · see citing works

Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases

Swierczynski, S., Klieser, E., Illig, R., Alinger-Scharinger, B., Kiesslich, T., & Neureiter, D. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1025047 · Cited by 44 · see citing works

An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives

Su, M., Gong, X.-Y., & Liu, F. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1877656 · Cited by 45 · see citing works

Differential molecular mechanistic behavior of HDACs in cancer progression

Singh, T., Kaur, P., Singh, P., Singh, S., & Munshi, A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01770-4 · Cited by 41 · see citing works

Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential

Raucci, A., Zwergel, C., Valente, S., & Mai, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01677 · Cited by 41 · see citing works

Skewed Expression of the Genes Encoding Epigenetic Modifiers in High-Risk Uveal Melanoma

Herlihy, N. S., Doğrusöz, M., van Essen, T. H., Harbour, J. W., van der Velden, P. A., van Eggermond, M. C. J. A., Haasnoot, G. W., van den Elsen, P. J., & Jager, M. J. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15250 · Cited by 41 · see citing works

Dendrite Development Regulated by the Schizophrenia-Associated Gene FEZ1 Involves the Ubiquitin Proteasome System

Watanabe, Y., Khodosevich, K. V., & Monyer, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.022 · Cited by 41 · see citing works

The Class IIa histone deacetylase HDAC4 and neuronal function: Nuclear nuisance and cytoplasmic stalwart?

Fitzsimons, H. L. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.06.006 · Cited by 41 · see citing works

Gene Expression Mapping of Histone Deacetylases and Co-factors and Correlation with Survival Time and 1H-HRMAS Metabolomic Profile in Human Gliomas

Dali‐Youcef, N., Froelich, S. C., Moussallieh, F., Chibbaro, S., Noël, G., Namer, I. J., Heikkinen, S., & Auwerx, J. H. (2015) · Scientific Reports · doi:10.1038/srep09087 · Cited by 41 · see citing works

Post-Translational Modifications That Drive Prostate Cancer Progression

Samaržija, I. (2021) · Biomolecules · doi:10.3390/biom11020247 · Cited by 39 · see citing works

Metal-dependent Deacetylases: Cancer and Epigenetic Regulators

López, J. E., Sullivan, E. D., & Fierke, C. A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01067 · Cited by 38 · see citing works

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma

Fabian, J., Opitz, D., Althoff, K., Lodrini, M., Hero, B., Volland, R., Beckers, A., Preter, K. D., Decock, A., Patil, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11662 · Cited by 38 · see citing works

Lysine Fatty Acylation: Regulatory Enzymes, Research Tools, and Biological Function

Komaniecki, G., & Lin, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.717503 · Cited by 37 · see citing works

Long non‑coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11

Huo, W., Qi, F., & Wang, K. (2020) · Oncology Reports · doi:10.3892/or.2020.7680 · Cited by 35 · see citing works

Molecular and Cellular Changes During Cancer Progression Resulting From Genetic and Epigenetic Alterations

Pruitt, K. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.001 · Cited by 35 · see citing works

Histone Deacetylase 11 Knockdown Blocks Larval Development and Metamorphosis in the Red Flour Beetle, Tribolium castaneum

George, S., & Palli, S. R. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00683 · Cited by 32 · see citing works

MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells

Cassandri, M., Pomella, S., Rossetti, A., Petragnano, F., Milazzo, L., Vulcano, F., Camero, S., Codenotti, S., Cicchetti, F., Maggio, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910671 · Cited by 32 · see citing works

Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice

Bai, P., Liu, Y., Yang, L., Ding, W., Mondal, P., Sang, N., Liu, G., Lü, X., Ho, T. T., Zhou, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01491 · Cited by 30 · see citing works

Targeting of histone deacetylases in brain tumors

Ecker, J., Witt, O., & Milde, T. (2013) · CNS Oncology · doi:10.2217/cns.13.24 · Cited by 30 · see citing works

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

Mostofa, A., Distler, A., Meads, M. B., Sahakian, E., Powers, J. J., Achille, A., Noyes, D., Wright, G., Fang, B., Izumi, V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151713 · Cited by 27 · see citing works

ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy

Park, S., Joo, S. H., Lee, N., Jang, W., Seo, J. H., & Jeong, C. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01359-x · Cited by 27 · see citing works

Angiogenic Factor With G Patch and FHA Domains 1 Is a Novel Regulator of Vascular Injury

Zhou, B., Zeng, S., Li, N., Yu, L., Yang, G., Yang, Y., Zhang, X., Fang, M., Xia, J., & Xu, Y. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.308992 · Cited by 27 · see citing works

Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice

Bryant, D., Landles, C., Papadopoulou, A. S., Benjamin, A. C., Duckworth, J. K., Rosahl, T. W., Benn, C., & Bates, G. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-11630-1 · Cited by 27 · see citing works

HDAC11: A novel target for improved cancer therapy

Liu, Y., Tong, X., Hu, W., & Chen, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115418 · Cited by 26 · see citing works

Acetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer

Lozada, E., Andrysík, Z., Yin, M., Redilla, N., Rice, K., & Stambrook, P. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7966 · Cited by 26 · see citing works

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Karati, D., Mukherjee, S., & Roy, S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02303-x · Cited by 25 · see citing works

Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer

Dai, Q., & Ye, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.793425 · Cited by 24 · see citing works

A bismuth diethyldithiocarbamate compound induced apoptosis via mitochondria-dependent pathway and suppressed invasion in MCF-7 breast cancer cells

Chan, P. F., Ang, K. P., & Hamid, R. A. (2021) · BioMetals · doi:10.1007/s10534-021-00286-0 · Cited by 23 · see citing works

Biological function and small molecule inhibitors of histone deacetylase 11

Jia, G., Liu, J., Hou, X., Jiang, Y., & Li, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116634 · Cited by 19 · see citing works

A pan‐cancer analysis identifies HDAC11 as an immunological and prognostic biomarker

Li, R., Wu, X., Zhao, P., Xue, K., & Li, J. (2022) · The FASEB Journal · doi:10.1096/fj.202101742rr · Cited by 19 · see citing works

The role of HDAC11 in obesity‐related metabolic disorders: A critical review

Yang, H., Chen, L., Sun, Q., Yao, F., Saeed, M., & Sun, C. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30286 · Cited by 19 · see citing works

Proliferative status regulates HDAC11 mRNA abundance in nontransformed fibroblasts

Bagui, T. K., Sharma, S. S., Ma, L., & Pledger, W. J. (2013) · Cell Cycle · doi:10.4161/cc.26433 · Cited by 18 · see citing works

Antitumor activity of novel POLA1-HDAC11 dual inhibitors

Dallavalle, S., Musso, L., Cincinelli, R., Darwiche, N., Gervasoni, S. I., Vistoli, G., Guglielmi, M. B., Porta, I. L., Pizzulo, M., Modica, E., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113971 · Cited by 17 · see citing works

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer

Guo, F., & Wang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1057186 · Cited by 17 · see citing works

Status of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population.

Singh, V. K., Singh, L. C., Singh, A., Sharma, J. D., Borthakur, B. B., Debnath, A., Rai, A. K., Phukan, R. K., Mahanta, J., Kataki, A. C., et al. (2015) · PubMed Central · Cited by 17 · see citing works

Utilization of an optimized AlphaFold protein model for structure‐based design of a selective HDAC11 inhibitor with anti‐neuroblastoma activity

Baselious, F., Hilscher, S., Hagemann, S., Tripathee, S., Robaa, D., Barinka, C., Hüttelmaier, S., Schutkowski, M., & Sippl, W. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400486 · Cited by 16 · see citing works

Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas

Irimia, R. M., & Piccaluga, P. P. (2024) · Cancers · doi:10.3390/cancers16193359 · Cited by 16 · see citing works

A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells

Lu, X., Yan, G., Dawood, M., Klauck, S. M., Sugimoto, Y., Klinger, A., Fleischer, E., Shan, L., & Efferth, T. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114677 · Cited by 16 · see citing works

Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects

Ramaiah, M. J., Naushad, S. M., Lavanya, A., Chatla, S., Devi, T. A., Sampathkumar, S., Dharan, D. B., & Bhadra, M. P. (2017) · Gene · doi:10.1016/j.gene.2017.06.031 · Cited by 16 · see citing works

Versatility of ARD1/NAA10-mediated protein lysine acetylation

Vo, T. T. L., Jeong, C., Lee, S., Kim, K., Ha, E., & Seo, J. H. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0100-7 · Cited by 17 · see citing works

The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis

Xu, L., Yan, X., Wang, J., Zhao, Y., Liu, Q., Fu, J., Shi, X., & Su, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015066 · Cited by 15 · see citing works

Unraveling HDAC11: Epigenetic orchestra in different diseases and structural insights for inhibitor design

Khatun, S., Bhagat, R. P., Dutta, R., Datta, A., Jaiswal, A., Halder, S., Jha, T., Amin, S. A., & Gayen, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116312 · Cited by 15 · see citing works

LncRNA C9orf139 can regulate the progression of esophageal squamous carcinoma by mediating the miR-661/HDAC11 axis

Yang, X., Shen, Z., Tian, M., Lin, Y., Li, L., Chai, T., Zhang, P., Kang, M., & Lin, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101487 · Cited by 14 · see citing works

HDAC11 displays neuropathological alterations and offers as a novel drug target for Alzheimer's disease

Bai, P., Mondal, P., Liu, Y., Gomm, A., Suen, C., Yang, L., Zhu, B., Sun, H., Ran, C., Shen, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14616 · Cited by 12 · see citing works

A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway.

Huang, P.-Y., Shih, I.-A., Liao, Y., You, H., & Lee, M. (2022) · PubMed Central · Cited by 12 · see citing works

Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays

Uba, A. İ., Hryb, M., Singh, M., Bui-Linh, C., Tran, A., Atienza, J., Misbah, S., Mou, X., & Wu, C. F. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122395 · Cited by 11 · see citing works

Identification of discriminative genes for predicting breast cancer subtypes

Etemadi, R., Alkhateeb, A., Rezaeian, I., & Rueda, L. G. (2016) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2016.7822688 · Cited by 10 · see citing works

Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer

Finnegan, E., Ding, W., Ude, Z., Terer, S., McGivern, T., Blümel, A. M., Kirwan, G., Shao, X., Genua, F., Yin, X.-F., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00882-x · Cited by 9 · see citing works

Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo

Wang, L., Bao, X., Yang, J., Li, H., Zhou, Q., Jiang, X., Li, M., Liu, X., Yuan, X., Sun, Y., et al. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.02.018 · Cited by 9 · see citing works

Transcriptomic changes throughout post-hatch development in Gallus gallus pituitary

Pritchett, E. M., Lamont, S. J., & Schmidt, C. J. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0186 · Cited by 7 · see citing works

HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285

Zhou, Z., Zhong, L., Chu, X., Wan, P., Dan, W., Shao, X., Chen, S., Zhang, Z., Lu, Y., & Liu, B. (2023) · Medical Oncology · doi:10.1007/s12032-023-02196-2 · Cited by 8 · see citing works

Histone Deacetylase Inhibitors in Cancer Prevention and Therapy

Movafagh, S., & Munson, A. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812494-9.00004-4 · Cited by 8 · see citing works

The Role of HATs and HDACs in Cell Physiology and Disease

Santos‐Barriopedro, I., Raurell‐Vila, H., & Vaquero, A. (2017) · Wiley eBooks · doi:10.1002/9783527697274.ch4 · Cited by 5 · see citing works

Substrate-Guided Development of HDAC11-Selective Inhibitors Featuring α-Amino Amide Zinc-Binding Groups

Hilscher, S., Meleshin, M., Baselious, F., Bařinka, C., Sippl, W., Schutkowski, M., & Schiene‐Fischer, C. (2025) · ACS Omega · doi:10.1021/acsomega.5c08195 · Cited by 4 · see citing works

Emerging role of HDAC11 in skeletal muscle biology

Chen, J., & Li, Q. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1368171 · Cited by 4 · see citing works

Protein Acetylation as an Integral Part of Metabolism in Cancer Development and Progression

Čuperlović‐Culf, M., & Culf, A. S. (2014) · Cited by 4 · see citing works

Epigenetic Treatment Options in Urothelial Carcinoma

Pinkerneil, M., Hoffmann, M. J., & Niegisch, G. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7234-0_21 · Cited by 4 · see citing works

Strong Involvement of Classical Histone Deacetylases and Mechanistically Distinct Sirtuins in Bellicose Cancers

Ganai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_4 · Cited by 4 · see citing works

HDAC11: the lone mystic member of Class IV HDAC

Kalle, A. M. (2019) · Revista de Fomento Social · doi:10.16943/ptinsa/2019/49577 · Cited by 3 · see citing works

Expression profiling of muscle invasive and non-invasive bladder tumors for biomarkers identification related to drug resistance, sensitivity and tumor progression

Antonova, O., Rukova, B. B., Mladenov, B. S., Rangelov, S., Hammoudeh, Z., Nesheva, D. V., Staneva, R., Spasova, V., Grigorov, E. E., Hadjidekova, S. P., et al. (2020) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2020.1778528 · Cited by 3 · see citing works

Influência do sulforafano, um inibidor de histonas desacetilases, sobre a instabilidade genômica e mecanismos epigenéticos em linhagens celulares humanas

dos Santos, P. W. D. S. (2019) · doi:10.11606/d.60.2019.tde-24052019-145414 · Cited by 2 · see citing works

Determination of expression level of AP1S1, CDK9, FIGF and HDAC11 genes in bladder tumors for aggressive phenotype characterization

Antonova, O., Hammoudeh, Z., Yordanova, Z. B., & Mladenov, B. S. (2023) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2023.2253926 · Cited by 1 · see citing works

Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models

Voutsadakis, I. A. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20404 · Cited by 1 · see citing works

Therapeutic Potential of HDAC Inhibitors in Neurodegenerative Diseases

Singh, A. K., Sudhan, Y. G., Chandana, S. L., Iyaswamy, A., & Durairajan, S. S. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-6099-8_14 · Cited by 2 · see citing works

Abstract 1742: Potential roles of histone deacetylase 11 in cell cycle regulation and cancer.

Srikumar, T., Telles, E., & Seto, E. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-1742

HDAC11: A novel target for improved cancer therapy

Liu, Y., Tong, X., Hu, W., & Chen, D. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115418 · Cited by 26 · see citing works

HDAC11: the lone mystic member of Class IV HDAC

Kalle, A. M. (2019) · Revista de Fomento Social · doi:10.16943/ptinsa/2019/49577 · Cited by 3 · see citing works

Genetic dissection of histone deacetylase requirement in tumor cells

Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L., & Olson, E. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903139106 · Cited by 110 · see citing works

A pan‐cancer analysis identifies HDAC11 as an immunological and prognostic biomarker

Li, R., Wu, X., Zhao, P., Xue, K., & Li, J. (2022) · The FASEB Journal · doi:10.1096/fj.202101742rr · Cited by 19 · see citing works